Zacks.com on MSN6d
Expanding Global Market, NuVasive Benefits to Aid GMED StockGlobus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products. Meanwhile, the company ...
Globus Medical, Inc.'s stock has surged due to a successful execution of the NuVasive deal and three consecutive guidance hikes, boosting investor confidence and valuation. The $3.1 billion ...
Globus Medical and NuVasive's merger marked its first year on Sept. 1, Globus' CEO Dan Scavilla said in a Nov. 5 earnings call.
Zacks.com on MSN22d
Is GMED Stock a Smart Addition to Your Portfolio Right Now?Globus Medical's synergistic merger with NuVasive and a cadence of product launches bring optimism to investors.
MyChesCo on MSN12d
Globus Medical Reports Robust Q3 2024 Financial Performance and Raises Annual OutlookGlobus Medical, Inc. (NYSE: GMED) has unveiled its financial success for the third quarter of 2024, showcasing notable growth ...
The stock carries a Zacks Rank #2 (Buy) currently. Globus Medical merged its business with NuVasive. The combined company has formed a global musculoskeletal company focused on rapid innovation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback